Invitrogen

P-cadherin Monoclonal Antibody (PCD-1)

Product Image Gallery

P-cadherin Antibody in Immunocytochemistry (ICC/IF) — Published figure using P-cadherin monoclonal antibody (Product # 13-2000Z) in Immunocytochemistry

P-cadherin Antibody in Immunohistochemistry (Paraffin) (IHC (P)) — Figure 7. Reduced epidermal PAR3 and increased P-cadherin levels at heterologous contacts correlate with progression of human melanoma. (A) H&E staining (top) and PAR3 and TRP2 immunostainings (bottom) of human normal skin and melanoma tissue. Bars: (top) 100 um; (bottom) 20 um. Data are representative of at least three independent experiments. (B) Quantification of epidermal anti-PAR3 immunoreactivity in normal skin epidermis ( n = 10 tissues from different donors), melanoma with tumor depth ~1 mm ( n = 9 tumors from different patients), and melanoma with tumor depth ~10 mm ( n = 8 tumors from different patients). Data are mean + SEM. *, P = 0.0113; **, P = 0.0040; one-way ANOVA with Tukey posthoc test. (C) P-cadherin and TRP2 costaining in melanoma in situ and melanoma with ~10 mm depth revealing high levels of P-cadherin at sites of KC-MC contacts. Bar, 10 um. Data are representative of at least three independent experiments. (D) P-cadherin immunostainings of human normal skin and melanoma tissue. Bar, 20 um. Data are representative of at least three independent experiments. (E) Quantification of anti-P-cadherin immunoreactivity in melanoma patients in KC-MC contacts of normal skin epidermis ( n = 9 tissues from different donors), melanoma in situ ( n = 9 tissues from different patients), melanoma with tumor depth ~1 mm ( n = 8 tumors from different patients), and ~10-mm melanoma ( n = 4 tumors from different patients). Data are pooled and depicted as mean + SEM. **, P = 0

P-cadherin Antibody in Western Blot, Immunohistochemistry (Paraffin) (WB, IHC (P)) — Figure 4. Par3 loss in KCs increases P-cadherin surface levels and stability and enforces P-cadherin localization to heterologous KC-MC contacts. (A) P-cadherin immunostaining in Par3 KO KC-MC co-culture and MC monoculture. Bar, 10 um. (B) P-cadherin immunostaining in control and Par3 KO co-cultures. Bar, 10 um. (C) P-cadherin and Par3 coimmunostainings of neonatal control skin cross sections depicting interfollicular epidermis (top) and hair follicle (bottom) areas. Dashed lines demarcate the MC-containing basal epidermal layer. Bar, 10 um. (D) P-cadherin and TRP2 immunohistochemistry of neonatal skin cross sections. Dashed lines underline the MC-containing basal epidermal layer. Bar, 10 um. (A-D) Data are representative of three independent experiments. (E) Quantification of the number of P-cadherin-positive cells in interfollicular epidermis (IFE; data are mean +- SD; n = 3 mice per group; ****, P < 0.0001; Student's t test) and MC number colocalizing with P-cadherin-positive cell clusters in hair follicles (data are pooled and depicted as mean +- SD; n = 5 mice per group; **, P = 0.0095; unequal variances Student's t test with Welch's correction). (F) Quantitative RT-PCR for P-cadherin RNA expression in control and Par3 KO primary KCs cultured at LC or 5 d HC. Data are pooled and represented as mean +- SEM. n = 5 biological replicates per group. LC: ns, P = 0.0940. HC: ns, P = 0.941. One-way ANOVA with Tukey posthoc test was used. (G) Western blot analysis

P-cadherin Antibody in Immunohistochemistry (IHC) — Figure 4. Depletion of Abi1 affects hair follicle development and distribution of the hair-follicle transcription factor SOX9. (A) Whole-mount immunofluorescence of control and Abi1-2082 KD E16.5 embryo immunostained for the hair follicle marker P-cadherin. (B and C) Quantification of data shown in A. Data are the means +- SD from four embryos per condition. *, P = 5 x 10 -3 (germs); *, P = 7 x 10 -5 (pegs) for control versus Abi1-2082 KD cells by unpaired t test. (D-F) Sagittal views of 10-um sections of dorsal skin from control and Abi1-2082 KD E16.5 embryos. Sections were immunostained for P-cadherin and SOX9. Arrows indicate abnormal distribution of SOX9. (G) Quantification of basal layer SOX9 staining shown in E and in sections from embryos injected in the same manner with shWasf2-493;H2B-GFP lentivirus. Data are the mean +- SD from four control, four Abi1, and three Wasf2 embryos. *, P = 0.0017 (Ctrl vs. Abi1-2082 ); *, P = 0.024 (Ctrl vs. Wasf2-493 ) by unpaired t test. (H) Whole-mount immunofluorescence of control and Abi1-2082 KD E16.5 embryos immunostained for SOX9. In the images, insets show the transduced cells (H2B - GFP + ), and dotted lines indicate the dermal-epidermal border. Nuclei were stained with DAPI (blue). Scale bars = 100 um (A), 20 um (D and F), and 50 um (E and H). FOV, field of view.

P-cadherin Antibody in Western Blot (WB) — Figure 6. P-cadherin expression is sufficient to induce MC dedifferentiation and hyperproliferation. (A) TRP2 immunostaining of back skin cross sections of P0 control and E-cad eKO mice. Data are representative of three independent experiments. (B) Quantification of MC number in interfollicular epidermis of control and E-cad eKO P0 back skin. Data are pooled and represented as mean +- SD. n = 3 mice per group. *, P = 0.0133; Student's t test. (C) Western blot analysis for P- and E-cadherin expression in control, E-cad KO (KO), and E-cad KO /P-cad KD (KK) KCs. Data are representative of three independent experiments. (D) Phase-contrast micrographs of MCs co-cultured with control (left), E-cad KO (middle), or E-cad KO / P-cad KD (right) KCs for 3 d at HC. Data are representative of three independent experiments. (E) Quantification of D (eight images per condition). Data are pooled and represented as mean +- SD. Dendritic length: n = 3 biological replicates per group; Ctrl versus KO: ***, P = 0.0003; KO versus KK: ***, P = 0.0005; one-way ANOVA with Tukey posthoc test. MC numbers: n = 3 biological replicates per group; Ctrl versus KO: **, P = 0.0038; KO versus KK: **, P = 0.0042; one-way ANOVA with Tukey posthoc test. (F) Western blot analysis for P-cadherin in control- and P-cadherin-expressing CHOs. Data are representative of two independent experiments. (G) Quantification of MC number co-cultured with control or P-cadherin overexpressing CHO cells for 4 d at HC (20 image

Product Details

Applications

Tested Dilution

Publications

Western Blot (WB)

10 µg/mL

View 2 publications 2 publications

Immunohistochemistry (IHC)

View 7 publications 7 publications

Immunohistochemistry (Paraffin) (IHC (P))

View 3 publications 3 publications

Immunohistochemistry (Frozen) (IHC (F))

Assay-dependent

View 2 publications 2 publications

Immunocytochemistry (ICC/IF)

View 7 publications 7 publications

Flow Cytometry (Flow)

View 1 publication 1 publication

Inhibition Assays (IA)

60 µg/mL

In vitro Assay (IV)

View 1 publication 1 publication

Miscellaneous PubMed (Misc)

View 4 publications 4 publications

Product Specifications

Species Reactivity

Mouse

Published species

Bovine, Fish, Hamster, Human, Mouse, Rat, Sheep, Tag

Host/Isotype

Rat / IgG2a

Class

Monoclonal

Type

Antibody

Clone

PCD-1

Immunogen

Mouse endoderm cell line PSA5-E.

Conjugate

Unconjugated

Form

Lyophilized

Concentration

2.0 mg/mL

Purification

Ion-exchange chromatography

Storage buffer

10mM PBS, pH 7.4, with 1% BSA

Contains

no preservative

Storage conditions

4° C

RRID

AB_2533006

Product Specific Information

Source: Monoclonal antibody was obtained by fusing the P3-X63-Ag8-U1 mouse myeloma cell-line with spleen cells of Donryu rat after immunization with mouse endoderm cell line PSA5-E.

Specificity: This antibody specifically reacts with mouse P-cadherin. This antibody inhibits P-cadherin-dependent cell-cell contact.

Cross reactivity: This antibody does not react with human or chicken P-cadherin.

Storage: 4°C This product does not contain preservative. The stock solution (2.0 mg/ml) should be stored in aliquots at -20°C for 1 year, or should be stored at 4°C for 6 months after adding 0.1% sodium azide. Avoid repeated freeze-thaw cycles.

Reconstitution: Dissolve the lyophilized antibody in 50 µl of distilled water (final concentration: 2.0 mg/ml). This solution can be used as a stock solution. If dilution is necessary for your application, dilute the stock solution with the following Dilution solution just prior to use. When the entire amount of antibody is to be used over a short time period, it may be dissolved directly in 500 µl or more of the Dilution solution. Be sure to store the antibody at a minimum concentration of 2.0 mg/ml. A lower antibody concentration may result in decreased stability. Reconstituted antibody solution should contain 0.1% sodium azide as a preservative when stored at 4°C.

Ca2+ should be contained in the buffers to stabilize cadherin antigen.

Target Information

P-cadherin, also known as Cadherin-3, is a Type 1 cadherin protein that belongs to the cadherin superfamily. Type 1 cadherins are single-pass transmembrane proteins that have 5 extracellular cadherin repeats and an intracellular domain that binds p120-catenin and beta-catenin. Cadherins are calcium-dependent cell-cell adhesion glycoproteins responsible for a range of processes including development, wound healing, cell-cell signaling, cell growth and differentiation. P-cadherin is expressed in human fetal structures, and in adult tissues such as the basal layer of the epidermis, breast, prostate, ovary, cervix, hair follicle, and corneal endothelium. P-cadherin expression has also been reported on embryonic stem cells, and stem cells of the normal mammary gland, and hair follicle. Overexpression of P-cadherin has been associated with poor prognosis in breast, prostate, ovary, colon, and stomach carcinomas. Mutations in CDH3 are associated with congential hypotrichosis with juvenile macular dystrophy.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.